Foresite Capital Opportunity Management V
Latest statistics and disclosures from Foresite Capital Opportunity Management V's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Pardes Biosciences, Theseus Pharmaceuticals, Gemini Therapeutics, CMPX, Kinnate Biopharma, and represent 78.84% of Foresite Capital Opportunity Management V's stock portfolio.
- Foresite Capital Opportunity Management V has $33M in assets under management (AUM), dropping by -16.06%.
- Central Index Key (CIK): 0001792207
Tip: Access up to 7 years of quarterly data
Positions held by Foresite Capital Opportunity Management V consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Foresite Capital Opportunity Management V
Foresite Capital Opportunity Management V holds 9 positions in its portfolio as reported in the September 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Pardes Biosciences | 29.0 | $9.7M | 5.2M | 1.85 |
|
|
| Theseus Pharmaceuticals | 16.7 | $5.6M | 959k | 5.80 |
|
|
| Gemini Therapeutics | 12.0 | $4.0M | 2.4M | 1.64 |
|
|
| Compass Therapeutics (CMPX) | 10.6 | $3.5M | 1.6M | 2.28 |
|
|
| Kinnate Biopharma | 10.5 | $3.5M | 292k | 11.95 |
|
|
| Adicet Bio (ACET) | 7.3 | $2.4M | 170k | 14.22 |
|
|
| Quantum-Si Incorporated Com Cl A (QSI) | 5.2 | $1.7M | 634k | 2.75 |
|
|
| Hims & Hers Health Com Cl A (HIMS) | 5.1 | $1.7M | 306k | 5.58 |
|
|
| Enanta Pharmaceuticals (ENTA) | 3.5 | $1.2M | 23k | 51.87 |
|
Past Filings by Foresite Capital Opportunity Management V
SEC 13F filings are viewable for Foresite Capital Opportunity Management V going back to 2021
- Foresite Capital Opportunity Management V 2022 Q3 filed Nov. 14, 2022
- Foresite Capital Opportunity Management V 2022 Q2 filed Aug. 12, 2022
- Foresite Capital Opportunity Management V 2022 Q1 filed May 13, 2022
- Foresite Capital Opportunity Management V 2021 Q4 filed Feb. 11, 2022